E. Taibi

3-month triptorelin in premenopausal patients with hormone receptor-positive early breast cancer: a commentary and a retrospective experience.

M. Caruso, F. Caruso, M. V. Sanó, 2015, Future oncology.

Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single-center experience.

F. Todaro, M. Caruso, M. V. Sanó, 2012, Future oncology.

Efficacy of Trastuzumab in Unselected Patients with HER2-Positive Metastatic Breast Cancer: A Retrospective Analysis

V. Torri, D. Generali, F. Atzori, 2014, Tumori.

Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.

C. Porta, G. Banna, U. de Giorgi, 2014, Future oncology.

Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.

C. Porta, G. Banna, U. de Giorgi, 2014, Future Oncology.